GlassScriptPhysician profile
Wayne Babcock
NPI 1548506827
$958.05
in general payments reported to CMS, 2019-2025
18 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.55 · 2023: $274 · 2024: $208 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848 · Consulting Fee: $20.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.07 |
| Consulting Fee | $20.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Oncology Corporate, INC. | $240.80 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.61 | 2022-2025 | Hyqvia, Glassia, Vpriv |
| Horizon Therapeutics Plc | $87.67 | 2023 | |
| Csl Behring | $63.31 | 2023-2024 | Hizentra |
| Boston Scientific Corporation | $62.85 | 2023-2024 | Exalt Model D |
| Lundbeck LLC | $58.27 | 2022-2024 | Vyepti |
| Tg Therapeutics, INC. | $48.60 | 2023-2025 | |
| Amgen INC. | $33.90 | 2024 | Krystexxa |
| Averitas Pharma INC. | $27.95 | 2024 | Qutenza |
| Octapharma USA, INC. | $26.64 | 2025 | Octagam Immune Globulin (Human) |
| Abbvie INC. | $22.49 | 2023 | |
| Alexion Pharmaceuticals, INC. | $21.99 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $21.83 | 2025 | Keytruda, Keytruda Qlex |
| Glaxosmithkline, LLC. | $21.32 | 2025 | Nucala |
| Genentech USA, INC. | $21.11 | 2023 | Xolair |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $20.43 | 2024 | |
| Fresenius Kabi USA, LLC | $16.06 | 2024 | |
| Lilly USA, LLC | $14.22 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Babcock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.